抗肥満薬の世界市場 2023-2027

当レポートでは抗肥満薬の市場規模は、2023年から2027年の間に136億9343万米ドルの増加が見込まれ、予測期間中に12.5%のCAGRで成長すると予測しています。当レポートでは、抗肥満薬市場の全体的な分析、市場規模と予測、動向、成長促進要因・課題、さらに約25社のベンダーを網羅したベンダー分析を行っています。

現在の世界の市場動向と促進要因、市場全体の環境に関する最新の分析を提供しています。

市場は、肥満人口の増加、病的肥満に対する限定的な肥満手術の利用、承認された薬剤の数が限られていることなどが要因となっています。

本調査では、肥満と2型糖尿病の両方をターゲットとする薬剤の研究が、今後数年間の抗肥満薬市場の成長を促進する主要な理由の1つであると特定しています。また、体重管理に関する意識、小児肥満や病的肥満の発生率の増加が、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2022
• 市場の見通し：2022-2027年の予測

第4章 市場規模実績

• 世界の抗肥満薬市場2017～2021年
• タイプセグメント分析2017-2021
• 医薬品クラスセグメント分析2017-2021
• 地域セグメント分析2017-2021
• 国セグメント分析2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 タイプ別の市場セグメンテーション

• 市場内訳
• タイプ別比較
• クラス III抗肥満薬 - 市場規模と予測 2022-2027
• クラス II抗肥満薬 - 市場規模と予測 2022-2027
• クラス I抗肥満薬 - 市場規模と予測 2022-2027
• タイプ別の市場機会

第7章 薬物クラス別市場セグメンテーション

• 市場内訳
• 薬剤クラス別比較
• 末梢作用薬 - 市場規模と予測 2022-2027
• 中枢作用薬 - 市場規模と予測 2022-2027
• 医薬品クラス別の市場機会

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米 - 市場規模と予測 2022-2027
• 欧州 - 市場規模と予測 2022-2027
• アジア - 市場規模と予測 2022-2027
• その他の地域（ROW） - 市場規模と予測 2022-2027
• 米国 - 市場規模と予測 2022-2027
• ドイツ - 市場規模と予測 2022-2027
• 英国 - 市場規模と予測 2022-2027
• カナダ - 市場規模と予測 2022-2027
• 中国 - 市場規模と予測 2022-2027
• 地域情勢別の市場機会

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Alvogen Iceland ehf
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Cadila Healthcare Ltd.
• Eli Lilly and Co.
• Empros Pharma AB
• ERX Pharmaceuticals Inc.
• Gelesis Inc.
• GlaxoSmithKline Plc
• Innovent Biologics Ltd.
• LG Chem
• Novo Nordisk AS
• Rhythm Pharmaceuticals Inc.
• SCOHIA PHARMA Inc.
• VIVUS LLC

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Type
• Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global anti-obesity drugs market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Type - Market share 2022-2027 (%)
• Exhibits31: Data Table on Type - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Type
• Exhibits33: Data Table on Comparison by Type
• Exhibits34: Chart on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibits46: Market opportunity by Type ($ million)
• Exhibits47: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibits48: Data Table on Drug Class - Market share 2022-2027 (%)
• Exhibits49: Chart on Comparison by Drug Class
• Exhibits50: Data Table on Comparison by Drug Class
• Exhibits51: Chart on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits52: Data Table on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Chart on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibits54: Data Table on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibits55: Chart on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits56: Data Table on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Chart on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibits58: Data Table on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibits59: Market opportunity by Drug Class ($ million)
• Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits63: Chart on Geographic comparison
• Exhibits64: Data Table on Geographic comparison
• Exhibits65: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits67: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits68: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits71: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits75: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits81: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits82: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits83: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits84: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits87: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits89: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits91: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits92: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits95: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits96: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits97: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits98: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits99: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits100: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits101: Market opportunity By Geographical Landscape ($ million)
• Exhibits102: Impact of drivers and challenges in 2022 and 2027
• Exhibits103: Overview on Criticality of inputs and Factors of differentiation
• Exhibits104: Overview on factors of disruption
• Exhibits105: Impact of key risks on business
• Exhibits106: Vendors covered
• Exhibits107: Matrix on vendor position and classification
• Exhibits108: Alvogen Iceland ehf - Overview
• Exhibits109: Alvogen Iceland ehf - Product / Service
• Exhibits110: Alvogen Iceland ehf - Key offerings
• Exhibits111: AstraZeneca - Overview
• Exhibits112: AstraZeneca - Product / Service
• Exhibits113: AstraZeneca - Key news
• Exhibits114: AstraZeneca - Key offerings
• Exhibits115: Boehringer Ingelheim International GmbH - Overview
• Exhibits116: Boehringer Ingelheim International GmbH - Business segments
• Exhibits117: Boehringer Ingelheim International GmbH - Key news
• Exhibits118: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits119: Boehringer Ingelheim International GmbH - Segment focus
• Exhibits120: Cadila Healthcare Ltd. - Overview
• Exhibits121: Cadila Healthcare Ltd. - Business segments
• Exhibits122: Cadila Healthcare Ltd. - Key news
• Exhibits123: Cadila Healthcare Ltd. - Key offerings
• Exhibits124: Cadila Healthcare Ltd. - Segment focus
• Exhibits125: Eli Lilly and Co. - Overview
• Exhibits126: Eli Lilly and Co. - Product / Service
• Exhibits127: Eli Lilly and Co. - Key offerings
• Exhibits128: Empros Pharma AB - Overview
• Exhibits129: Empros Pharma AB - Product / Service
• Exhibits130: Empros Pharma AB - Key offerings
• Exhibits131: ERX Pharmaceuticals Inc. - Overview
• Exhibits132: ERX Pharmaceuticals Inc. - Product / Service
• Exhibits133: ERX Pharmaceuticals Inc. - Key offerings
• Exhibits134: Gelesis Inc. - Overview
• Exhibits135: Gelesis Inc. - Product / Service
• Exhibits136: Gelesis Inc. - Key news
• Exhibits137: Gelesis Inc. - Key offerings
• Exhibits138: GlaxoSmithKline Plc - Overview
• Exhibits139: GlaxoSmithKline Plc - Business segments
• Exhibits140: GlaxoSmithKline Plc - Key offerings
• Exhibits141: GlaxoSmithKline Plc - Segment focus
• Exhibits142: Innovent Biologics Ltd. - Overview
• Exhibits143: Innovent Biologics Ltd. - Product / Service
• Exhibits144: Innovent Biologics Ltd. - Key offerings
• Exhibits145: LG Chem - Overview
• Exhibits146: LG Chem - Business segments
• Exhibits147: LG Chem - Key news
• Exhibits148: LG Chem - Key offerings
• Exhibits149: LG Chem - Segment focus
• Exhibits150: Novo Nordisk AS - Overview
• Exhibits151: Novo Nordisk AS - Business segments
• Exhibits152: Novo Nordisk AS - Key offerings
• Exhibits153: Novo Nordisk AS - Segment focus
• Exhibits154: Rhythm Pharmaceuticals Inc. - Overview
• Exhibits155: Rhythm Pharmaceuticals Inc. - Product / Service
• Exhibits156: Rhythm Pharmaceuticals Inc. - Key offerings
• Exhibits157: SCOHIA PHARMA Inc. - Overview
• Exhibits158: SCOHIA PHARMA Inc. - Product / Service
• Exhibits159: SCOHIA PHARMA Inc. - Key news
• Exhibits160: SCOHIA PHARMA Inc. - Key offerings
• Exhibits161: VIVUS LLC - Overview
• Exhibits162: VIVUS LLC - Product / Service
• Exhibits163: VIVUS LLC - Key offerings
• Exhibits164: Inclusions checklist
• Exhibits165: Exclusions checklist
• Exhibits166: Currency conversion rates for US$
• Exhibits167: Research methodology
• Exhibits168: Validation techniques employed for market sizing
• Exhibits169: Information sources
• Exhibits170: List of abbreviations

Technavio has been monitoring the anti-obesity drugs market and it is poised to grow by $13,693.43 mn during 2023-2027, accelerating at a CAGR of 12.5% during the forecast period. Our report on the anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing obese population, the use of bariatric surgery limited for morbid obesity, and the limited number of approved drugs.

Technavio's anti-obesity drugs market is segmented as below:

By Type

• Class III anti-obesity drugs
• Class II anti-obesity drugs
• Class I anti-obesity drugs

By Drug Class

• Peripherally acting drugs
• Centrally acting drugs

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the research on drugs that target both obesity and type 2 diabetes mellitus as one of the prime reasons driving the anti-obesity drugs market growth during the next few years. Also, awareness about weight management and an increase in childhood obesity and morbid obesity incidence will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the anti-obesity drugs market covers the following areas:

• Anti-obesity drugs market sizing
• Anti-obesity drugs market forecast
• Anti-obesity drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Alvogen Iceland ehf, Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and LG Chem. Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global anti-obesity drugs market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global anti-obesity drugs market 2017 - 2021 ($ million)
• 4.2 Type Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
• 4.3 Drug class Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 30: Chart on Type - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
• 6.2 Comparison by Type
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type
• 6.3 Class III anti-obesity drugs - Market size and forecast 2022-2027
• Exhibit 34: Chart on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Class III anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Class III anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• 6.4 Class II anti-obesity drugs - Market size and forecast 2022-2027
• Exhibit 38: Chart on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Class II anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Class II anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• 6.5 Class I anti-obesity drugs - Market size and forecast 2022-2027
• Exhibit 42: Chart on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Class I anti-obesity drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Class I anti-obesity drugs - Year-over-year growth 2022-2027 (%)
• 6.6 Market opportunity by Type
• Exhibit 46: Market opportunity by Type ($ million)

7 Market Segmentation by Drug Class

• 7.1 Market segments
• Exhibit 47: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibit 48: Data Table on Drug Class - Market share 2022-2027 (%)
• 7.2 Comparison by Drug Class
• Exhibit 49: Chart on Comparison by Drug Class
• Exhibit 50: Data Table on Comparison by Drug Class
• 7.3 Peripherally acting drugs - Market size and forecast 2022-2027
• Exhibit 51: Chart on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on Peripherally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Peripherally acting drugs - Year-over-year growth 2022-2027 (%)
• 7.4 Centrally acting drugs - Market size and forecast 2022-2027
• Exhibit 55: Chart on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Centrally acting drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Centrally acting drugs - Year-over-year growth 2022-2027 (%)
• 7.5 Market opportunity by Drug Class
• Exhibit 59: Market opportunity by Drug Class ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 63: Chart on Geographic comparison
• Exhibit 64: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.10 Canada - Market size and forecast 2022-2027
• Exhibit 93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.11 China - Market size and forecast 2022-2027
• Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 101: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 102: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 104: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 105: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 106: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 107: Matrix on vendor position and classification
• 12.3 Alvogen Iceland ehf
• Exhibit 108: Alvogen Iceland ehf - Overview
• Exhibit 109: Alvogen Iceland ehf - Product / Service
• Exhibit 110: Alvogen Iceland ehf - Key offerings
• 12.4 AstraZeneca
• Exhibit 111: AstraZeneca - Overview
• Exhibit 112: AstraZeneca - Product / Service
• Exhibit 113: AstraZeneca - Key news
• Exhibit 114: AstraZeneca - Key offerings
• 12.5 Boehringer Ingelheim International GmbH
• Exhibit 115: Boehringer Ingelheim International GmbH - Overview
• Exhibit 116: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 117: Boehringer Ingelheim International GmbH - Key news
• Exhibit 118: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 119: Boehringer Ingelheim International GmbH - Segment focus
• 12.6 Cadila Healthcare Ltd.
• Exhibit 120: Cadila Healthcare Ltd. - Overview
• Exhibit 121: Cadila Healthcare Ltd. - Business segments
• Exhibit 122: Cadila Healthcare Ltd. - Key news
• Exhibit 123: Cadila Healthcare Ltd. - Key offerings
• Exhibit 124: Cadila Healthcare Ltd. - Segment focus
• 12.7 Eli Lilly and Co.
• Exhibit 125: Eli Lilly and Co. - Overview
• Exhibit 126: Eli Lilly and Co. - Product / Service
• Exhibit 127: Eli Lilly and Co. - Key offerings
• 12.8 Empros Pharma AB
• Exhibit 128: Empros Pharma AB - Overview
• Exhibit 129: Empros Pharma AB - Product / Service
• Exhibit 130: Empros Pharma AB - Key offerings
• 12.9 ERX Pharmaceuticals Inc.
• Exhibit 131: ERX Pharmaceuticals Inc. - Overview
• Exhibit 132: ERX Pharmaceuticals Inc. - Product / Service
• Exhibit 133: ERX Pharmaceuticals Inc. - Key offerings
• 12.10 Gelesis Inc.
• Exhibit 134: Gelesis Inc. - Overview
• Exhibit 135: Gelesis Inc. - Product / Service
• Exhibit 136: Gelesis Inc. - Key news
• Exhibit 137: Gelesis Inc. - Key offerings
• 12.11 GlaxoSmithKline Plc
• Exhibit 138: GlaxoSmithKline Plc - Overview
• Exhibit 139: GlaxoSmithKline Plc - Business segments
• Exhibit 140: GlaxoSmithKline Plc - Key offerings
• Exhibit 141: GlaxoSmithKline Plc - Segment focus
• 12.12 Innovent Biologics Ltd.
• Exhibit 142: Innovent Biologics Ltd. - Overview
• Exhibit 143: Innovent Biologics Ltd. - Product / Service
• Exhibit 144: Innovent Biologics Ltd. - Key offerings
• 12.13 LG Chem
• Exhibit 145: LG Chem - Overview
• Exhibit 146: LG Chem - Business segments
• Exhibit 147: LG Chem - Key news
• Exhibit 148: LG Chem - Key offerings
• Exhibit 149: LG Chem - Segment focus
• 12.14 Novo Nordisk AS
• Exhibit 150: Novo Nordisk AS - Overview
• Exhibit 151: Novo Nordisk AS - Business segments
• Exhibit 152: Novo Nordisk AS - Key offerings
• Exhibit 153: Novo Nordisk AS - Segment focus
• 12.15 Rhythm Pharmaceuticals Inc.
• Exhibit 154: Rhythm Pharmaceuticals Inc. - Overview
• Exhibit 155: Rhythm Pharmaceuticals Inc. - Product / Service
• Exhibit 156: Rhythm Pharmaceuticals Inc. - Key offerings
• 12.16 SCOHIA PHARMA Inc.
• Exhibit 157: SCOHIA PHARMA Inc. - Overview
• Exhibit 158: SCOHIA PHARMA Inc. - Product / Service
• Exhibit 159: SCOHIA PHARMA Inc. - Key news
• Exhibit 160: SCOHIA PHARMA Inc. - Key offerings
• 12.17 VIVUS LLC
• Exhibit 161: VIVUS LLC - Overview
• Exhibit 162: VIVUS LLC - Product / Service
• Exhibit 163: VIVUS LLC - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 164: Inclusions checklist
• Exhibit 165: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 166: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 167: Research methodology
• Exhibit 168: Validation techniques employed for market sizing
• Exhibit 169: Information sources
• 13.5 List of abbreviations
• Exhibit 170: List of abbreviations